Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Gemcitabin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Gemcitabin Testmiljö

Gemcitabin

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Food and Drug Administration (FDA). Drug label - GEMZAR (gemcitabine). Drugs@FDA [www]. [updated 2005-04-20, cited 2022-10-14].

  2. Gemcitabine Accord (gemcitabine). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2022-10-24, cited 2022-11-08]

  3. Zhou J, Fang CX, Shen J, Schipper MJ, Zalupski MM, Minter RM et al. Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy. Am J Clin Oncol. 2017;40(5):517-522.

  4. Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110(8):1943-9.

  5. Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol. 2013;19(28):4511-9.

  6. Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017;80(1):209-215.

  7. Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T et al. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan. Urol Oncol. 2017;35(2):38e1-38e8.

  8. Canova S, Cicchiello F, Agustoni F, Bianchini G, Abbate MI, Bidoli P et al. Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients. Tumori. 2017;103(2):143-147.

  9. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-94.

  10. Saito Y, Takekuma Y, Komatsu Y, Sugawara M. Evaluation of risk factors for chemotherapy-induced nausea and vomiting in cisplatin and gemcitabine treatment for biliary tract cancer: acid suppressants do not prevent nausea. Pharmazie. 2022;77(6):196-201.

  11. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Food and Drug Administration (FDA). Drug label - GEMZAR (gemcitabine). Drugs@FDA [www]. [updated 2005-04-20, cited 2022-10-14].
  2. Gemcitabine Accord (gemcitabine). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2022-10-24, cited 2022-11-08]
  3. Zhou J, Fang CX, Shen J, Schipper MJ, Zalupski MM, Minter RM et al. Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy. Am J Clin Oncol. 2017;40(5):517-522.
  4. Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110(8):1943-9.
  5. Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol. 2013;19(28):4511-9.
  6. Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017;80(1):209-215.
  7. Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T et al. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan. Urol Oncol. 2017;35(2):38e1-38e8.
  8. Canova S, Cicchiello F, Agustoni F, Bianchini G, Abbate MI, Bidoli P et al. Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients. Tumori. 2017;103(2):143-147.
  9. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-94.
  10. Saito Y, Takekuma Y, Komatsu Y, Sugawara M. Evaluation of risk factors for chemotherapy-induced nausea and vomiting in cisplatin and gemcitabine treatment for biliary tract cancer: acid suppressants do not prevent nausea. Pharmazie. 2022;77(6):196-201.
  11. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]